

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Yidu Tech Inc.**  
**醫渡科技有限公司**

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 2158)

## ANNUAL RESULTS ANNOUNCEMENT FOR THE FISCAL YEAR ENDED 31 MARCH 2022

The board (the “**Board**”) of directors (the “**Directors**”) of Yidu Tech Inc. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) is pleased to announce the annual results of the Group for the fiscal year ended 31 March 2022 (the “**Reporting Period**”), together with the comparative figures for the fiscal year ended 31 March 2021. The results have been reviewed by the Company’s audit committee.

In this announcement, “we”, “us”, and “our” refer to the Company and where the context otherwise requires, the Group.

### FINANCIAL HIGHLIGHTS

	Year ended 31 March		
	2022	2021	Change (%)
	<i>(RMB'000, except percentages)</i>		
Revenue	1,237,200	867,036	42.7%
— Big Data Platform and Solutions	444,891	401,884	10.7%
— Life Sciences Solutions	359,375	184,318	95.0%
— Health Management Platform and Solutions	424,941	252,129	68.5%
— Others	7,993	28,705	(72.2%)
Gross profit	399,445	327,336	22.0%
Operating loss	(767,398)	(453,286)	69.3%
Loss for the year	(766,360)	(3,694,817)	(79.3%)
Non-IFRS adjusted net loss <sup>(1)</sup>	(583,521)	(275,079)	112.1%

(1) We define “adjusted net loss” as loss for the year and adding back (i) fair value changes of convertible redeemable preferred shares, (ii) fair value changes of convertible notes, (iii) fair value changes of warrants, (iv) share-based compensation expenses, and (v) listing expenses.

The Board did not recommend the distribution of a final dividend for the fiscal year ended 31 March 2022.

## BUSINESS REVIEW

The COVID-19 pandemic spreading across the globe has resulted in enormous challenges and uncertainties to societies and economies. In the new norm precipitated by management of the pandemic, the value of the public health management model empowered by digital technologies and artificial intelligence (AI) has been further validated.

With the national strategy focusing on high-quality development driven by innovation, China has been continually investing in digital infrastructure to transform the healthcare industry. According to the “14th Five-Year Plan”, China’s digital economy is expected to account for 10% of GDP in 2025. This includes the huge growth potential in the healthcare intelligence industry.

To achieve healthy and sustainable growth, Chinese legislators have enacted several pieces of legislation, including the Data Security Law and Personal Information Protection Law, to encourage scientific and technological innovations, always with safety as the key consideration. We fully support these laws as they point out the direction for the healthcare intelligence industry. Such market-friendly policies and better regulated market conditions enable us to deepen our core technologies and capabilities, to achieve our vision of “green healthcare”.

As a leading company in the healthcare intelligence industry, we are at the forefront in terms of applying AI and big data technologies to empower the digital transformation of the healthcare industry along the entire supply chain for higher efficiency. We embrace our social responsibility by leveraging our state-of-the-art technology to combat the pandemic and meet the diverse needs of our customers in the entire healthcare ecosystem.

Our healthcare intelligence infrastructure YiduCore comprises algorithms and insightful medical knowledge that are continuously accumulated and rapidly iterated as we expand our use-case scenarios with proper authorization. As of 31 March 2022, YiduCore processed and analyzed more than 2.6 billion healthcare records from over 600 million patients, covering over 800 hospitals. Through our focused efforts, we have made significant breakthroughs in public health, research, and diagnosis and treatment scenarios.

According to the Frost & Sullivan Report, the market size of China’s healthcare intelligence industry is expected to exceed RMB1.1 trillion in 2030. As a leading company in this sector with state-of-the-art technology and deep insights, we achieved strong growth for the year ended 31 March 2022 (“FY2022”) despite the challenging external environment.

Our total revenue for FY2022 reached RMB1,237.2 million, representing a year-on-year increase of 42.7%. As of 31 March 2022, we provided solutions for 82 top research hospitals in China and 26 regulators and policy makers, an increase of 6 hospitals and 7 regulators and policy makers respectively during the Reporting Period. The number of active life science customers that the Group served reached 141 as of 31 March 2022, an increase of 33 from 108 customers as of 31 March 2021. The number of active users who completed at least one transaction on our health management platform reached 12 million, more than doubled the approximately 5 million users as of 31 March 2021.

According to the Frost & Sullivan Report, we ranked No. 1 in terms of revenue in the medical institutions and regulators healthcare intelligence market, No. 1 in terms of revenue in the emerging healthcare intelligence market, and No. 1 in terms of revenue in the total healthcare intelligence market. Specifically, we have a 25.6% share of the emerging healthcare intelligence market.

We also have a strong focus on the environmental, social and governance (ESG) sector. We strive to promote people's well-being and public welfare through our innovative and advanced AI technology. Based on a deep understanding of epidemiology and transmission rules of infectious diseases, our advanced AI technologies and algorithms can cope with all of the 40 infectious diseases defined by the Chinese Center for Disease Control and Prevention (China CDC). With the combination of advanced algorithms and insight of infectious diseases, our public health management solutions are able to slow down the spread of infectious diseases and reduce the possibility of death while maintaining life normality. During the Reporting Period, we have abundant examples of assisting in slowing down the spread of COVID-19. In addition, the Real-World Data (RWD) Clinical Research Platform (Phase I) in Hainan Boao Lecheng that we constructed began trial operations in January 2022. Leveraging high quality real-world evidence (RWE), the platform aims to accelerate approvals for urgently-needed drugs and devices that have not been registered in China. Through our AI technology, we empowered the Hui Min Bao products, a city-level supplementary insurance to the existing national social medical insurance, during the Reporting Period in terms of insurance coverage to increase the affordability for patients.

YiduCore, our intelligent “medical brain”, supports our customers and partners in unlocking the value of health data to drive better outcomes by enabling the secure applicability of high-quality data in different use-case scenarios. This has been made possible by our commitment to “green healthcare” and years of continued investments.

Going forward, we will remain driven by our mission “to make value-based precision healthcare accessible to everyone”, utilizing big data and AI technology to bring forth “green healthcare” and improve the welfare of the society.

## **YiduCore**

YiduCore, our healthcare intelligence infrastructure, represents our core capabilities that can be understood in terms of three layers. The first layer is our data processing capabilities, which allow us to aggregate and convert the raw and scattered data on the information technology systems of hospitals and healthcare institutions into computable, structured and standardized data that can be analyzed with speed, accuracy and cost-efficiency. The second layer consists of our medical knowledge, insights and disease models that are continuously reinforced and expanded as they are applied to our data-analytics driven solutions for our customers in the various use-case scenarios. The final layer is our scenario-specific operations and service capabilities that we develop to help our customers better realize the value of our solutions and our ecosystem to achieve their target outcomes.

We have been committed, since day one, to research, development and independent innovation. We have continuously invested capital and resources to deepen our understanding of diseases while ensuring the security of our technical architecture as the foundation. As of 31 March 2022, the number of diseases covered by YiduCore's disease knowledge graphs had exceeded 9,000, an increase of more than 1,000 diseases compared to six months earlier. Based on YiduCore's modelling and technical capabilities, we have undertaken 6 national projects sponsored by central government authorities such as the Ministry of Science and Technology of the People's Republic of China with partners including renowned hospitals, regulators and research universities. We independently developed the Medical Data Intelligence Platform and Disease Registry Intelligent Research Platform, which has been certified by the China Information Technology Security Evaluation Center. This makes us the only healthcare technology company in China that has passed the authoritative national-level certification. We are also one of the only three healthcare technology companies in China that were certified by the China Academy of Information and Communications Technology (CAICT) for our secure multi-party computation and federated learning capabilities. All of the above-mentioned honors are recognition of our independent innovation and privacy protection abilities by the state and industry.

The models and algorithms in YiduCore are standardized and extensible, and they can be assembled to form solutions that adapt to diverse needs and use-case scenarios of the healthcare industry. By generating objective, measurable and traceable results, the solutions enable more precise decisions that increase efficiency and reduce waste on the supply side. Powered by our accumulated disease knowledge graphs and logical knowledge base, our data quality model, for example, applies quality control algorithms and neural network algorithms to automatically detect the missing data and logical errors in diagnosis and treatment records, and corrects the errors detected in an intelligent manner. The model can be part of the diagnosis-related groups solutions provided to hospital clients. With the proper authorization, it can offer reliable evidence supporting assessments of disease type mix and improvements in hospital operational efficiency. It can also be used in the scenario of Hui Min Bao to enhance risk management and improve the sustainability of the insurance. During the Reporting Period, we processed over 10 million pieces of medical insurance data in Hui Min Bao services in a northern city of China with our intelligent algorithms, and the accuracy rate of pre-existing conditions identified by the algorithms exceeded 90%.

Leveraging YiduCore, the effectiveness and value of our analytics solutions have been proved in a variety of use-case scenarios.

- Public Health

Our comprehensive public health solutions provide large-scale simulation and prediction that can proactively assess risks, optimize resource allocation and enable efficient and dynamic decision-making. As of 31 March 2022, the effectiveness and accuracy of our pandemic response and prediction algorithms had been validated in 18 cities, reducing mortality rates while assisting economic growth. Our risk prediction and policy simulation models allowed one of the local authorities in Guangdong Province to effectively plot the outbreak curve and formulate a lockdown strategy accordingly. The plotted outbreak curve accurately predicted the actual evolution, with the variance falling within only 5 cases. In addition, we also provided technical support and services for COVID-19 response in the Beijing 2022 Winter Olympic and Paralympic Games. Furthermore,

we are also working with partners including Tsinghua University and the China CDC to develop an intelligent application to cope with major global outbreaks of infectious diseases. The program has been listed as a “New Generation Artificial Intelligence” program by the Ministry of Science and Technology of the People’s Republic of China.

- Research

We increase the productivity of research-grade evidence generation and accelerate the delivery of affordable and high-quality care to patients in need. Nearly 1,000 research projects have been launched with our support. We also undertook the development of Real-World Data (RWD) Clinical Research Platform (Phase I) in Hainan Boao Lecheng, with tens of millions of contract value. The platform was put into trial operation in January 2022. It aims to promote the application of RWD and accelerate the approval of fast-track drugs and devices that are urgently needed in China for clinical purposes. It also facilitates researchers and regulators in generating and evaluating evidence of efficacy and safety in real-world clinical setting.

- Diagnosis and Treatment

We aim to fulfill our mission of making precision healthcare accessible for everyone by staying patient-centric and outcome-based. During the Reporting Period, we actively participated in the screening and managing of cancer, and early prevention and treatment of chronic hepatitis B in a city in Guangdong. By building an intelligent tumor risk prediction model, hospital intelligent follow-up platform, out of hospital patient management platform and other intelligent tools, we created a closed-loop of management from screening, diagnosis and treatment to follow-up, and thus promoted the health management of residents throughout their life cycle. We have completed the screening of over 100,000 residents in this city and advanced the process of follow-up visits of high-risk patients in an orderly manner.

### **Big Data Platform and Solutions (“BDPS”)**

In the BDPS segment, we provide data intelligence platforms and data analytics-driven solutions to hospitals, other healthcare institutions, regulators and policy makers. Despite the negative impact of COVID-19, this segment still maintained solid growth in FY2022. During the Reporting Period, the revenue of this segment reached RMB444.9 million, an increase of 10.7% compared to the fiscal year ended 31 March 2021. The number of top-notch hospital clients increased by 6 to 82 in total, while the number of regulator and policy-maker clients grew by 7 to 26.

By installing our data intelligence platform upon proper authorization, hospitals, regulators and policy-makers can achieve more in-depth governance of their multi-source heterogeneous data and transform it into structured, standardized and high-quality data. We also provide data analytics-driven applications and solutions that unlock the value of healthcare data to help clients make precise and efficient decisions. According to the Frost & Sullivan Report, the total addressable market for medical institutions and regulators in the China’s healthcare intelligence industry is expected to reach RMB200 billion by 2030.

The applications and solutions we offer to hospitals focus on three use-case scenarios, namely research, clinical diagnosis and treatment, and hospital operations management. By using our disease registries and disease research networks, top hospitals and experts can accelerate the production of research-grade evidence and scale up their clinical research in a faster and safer manner. As of 31 March 2022, our disease registries had covered 60 disease areas. Nearly 140 papers on our disease registries and data intelligence platforms have been published in prestigious journals, including Nature Medicine and Lancet Oncology.

In providing hospitals with solutions and applications, we keep iterating real-world disease models by using symbolic knowledge inference models and AI technologies such as deep learning. We continue to deepen disease insights and engage top-grade hospitals and experts in our research network, thus empowering our Life Sciences Solutions segment and achieving synergy among different business segments. Some notable achievements are as follows:

- In the field of solid tumors, as of 31 March 2022, our disease registries have covered more than 20 cancer types, including 9 of the 10 most common cancers in China. The hospital/doctor networks we have built and the real-world disease insights we have gained in the field of solid tumors can empower the clinical development of drugs and medical devices as well as real-world studies.
- In terms of ophthalmology, we won a contract for the construction of the National Clinical Research Center (NCRC) of the Eye Hospital of Wenzhou Medical University during the Reporting Period, with the contract value exceeding RMB10 million. As of 31 March 2022, we have partnered with top eye hospitals in North, East and South China. We continue to refine real-world disease insights and models to empower clinical evaluation of ophthalmic drugs and medical devices, and facilitate new technologies and new therapies in the clinical setting.
- In the area of hematologic disease, we have partnered with two of the country's only three hematologic disease NCRC hospitals in developing national disease registries and carrying out efficient clinical trials and cross-institutional RWE-based research. As of 31 March 2022, more than 20 clinical studies and trials have been supported by our NCRC hospitals, an increase of 6 over the first half of the fiscal year.

We processed and analyzed more abundant and diverse data for regulators and policy makers as part of our solutions for enhancing public health and regional population health. The COVID-19 pandemic has driven home to regulators the importance of public health management, and increased the funding available in this area. As the needs of our clients grew, the public health solutions that we offer also expanded from pandemic response to coping with all of the 40 infectious diseases defined by the China CDC. By analyzing fine and rich regional health data, regulators can explore health status, basic medical insurance burden and risk trends of the regional populations. With the analytical tools and simulation models we provide, regulators can develop corresponding policies

and measures and, at the same time, manage and allocate healthcare resources more effectively. This also presents an opportunity for us to expand public health solutions to regional population health management. Our regional platforms and solutions can also help regulators integrate medical resources and research forces in the region, and accelerate the development and implementation of the healthcare industry ecology. During the Reporting Period, we won the bid for Tianjin Clinical Research Center Big Data Platform, with a contract value of RMB39 million.

### **Life Sciences Solutions (“LSS”)**

Leveraging YiduCore and our network of top-grade hospitals and experts accumulated through our BDPS segment, we currently provide analytics-driven clinical development, RWE-based research and digital commercialization solutions in respect of the full life-cycle of a drug or a medical device from clinical development to post-market commercialization. We combine our deep understanding of diseases with the rich clinical experience of the team to help pharmaceutical, biotech, medical device and other companies involved in the clinical development process to reduce the time and costs of drug and medical device development while enhancing commercial success.

During the Reporting Period, the segment’s revenue amounted to RMB359.4 million, up by 95.0% year-on-year. The gross profit margin was 24.7%, an increase of three percentage points year-on-year. Over the past year, the LSS segment maintained strong growth momentum, especially in the analytics-driven clinical development solutions. We have built strategic partnerships with multiple innovative biotech companies. During the Reporting Period, we signed a strategic agreement with Zhaoke Ophthalmology, a company specializing in ophthalmic drug innovation and development. This partnership led to a Phase III clinical trial of a drug pipeline for fundus lesions. The project is led by Professor Chen Youxin, Director of Ophthalmology at Peking Union Medical College Hospital, and the first advisory board meeting has been completed. In the field of solid tumors, we conducted a Phase IV clinical trial sponsored by a well-known innovative biotech company, with a contract value of over RMB10 million.

Our capabilities in generating high-quality RWE to empower life science clients to manage and optimize the entire product life-cycle, from obtaining drug approval, peri-launch evidence support, post-marketing growth, to label extension, have all been validated. During the Reporting Period, we conducted a comprehensive retrospective real-world study for a top 20 MNC client and obtained approval from the CDE (Center for Drug Evaluation, National Medical Products Administration) for label revision of the client’s antibiotic drug. The approved revision has reduced the drug’s complexity of use. Furthermore, with our expertise in prospective real-world study, we conducted a post-marketing safety and efficacy commitment study on a new drug for blood disease sponsored by an innovative pharmaceutical company.

As we empower an increasing number of projects of all types, we have earned a good reputation in the life science industry, which is evidenced by our ability to engage a variety of clients. During the Reporting Period, our active clients grew from 108 to 141 and our core pharmaceutical, biotech and medical device company customers increased from 80 to 107. The overall revenue retention rate for all our clients was 122%, while the revenue retention of our core pharmaceutical, biotech and medical device clients was 130%. Among our top 20 clients, there are 8 international pharmaceutical companies and 13 listed companies.

We are building a team of professionals with rich experience and cross-domain expertise. As of 31 March 2022, we have approximately 500 employees in our Life Sciences Solutions segment with an average of 8 years of relevant experience in clinical research, data science, epidemiology, biostatistics, medical informatics, AI and others. While we continue to grow our team, we are also working to improve operational efficiency by using self-developed tools to algorithmize the accumulated medical experience, which was reflected in the increase in the gross profit margin.

### **Health Management Platform and Solutions (“HMPS”)**

Our HMPS segment continued to experience huge growth. During the Reporting Period, the revenue of this segment recorded a year-on-year increase of 68.5%.

In order to realize our mission of making value-based precision healthcare accessible to everyone, we offer innovative insurance technology and solutions to insurance companies, agencies and related regulators and policy makers within this segment. Leveraging our data processing capability and medical insights powered by YiduCore, our solutions aim at enabling our customers to design and develop innovative insurance products, facilitating faster and more accurate insurance underwriting and expediting claim processing. During the Reporting Period, we continued to increase our market penetration of the Hui Min Bao business. As of 31 March 2022, we have served 1 province and 9 cities, for a total of 22 cities, including Jiangsu province (including 13 prefecture-level cities), Beijing, Ningbo, Chongqing and Hefei, most of which are among China’s top 50 cities in terms of GDP in 2021. We served as the main operating platform, providing product design, user acquisition, promotion, customer services and claim management for Beijing Pu Hui Jian Kang Bao that was innovated in terms of insurance coverage to increase affordability for patients. Beijing Pu Hui Jian Kang Bao includes 75 urgently-needed drugs and devices that are available at Hainan Boao Lecheng but have not been registered in China. The high quality user base and large scale user operation enable us to increase user traffic from Hui Min Bao and improve our brand awareness among the general population, as well as explore further opportunities in public health.

We also deliver integrated healthcare solutions by leveraging technology capabilities and medical knowledge powered by YiduCore. We provide AI-empowered and one-stop analytics-driven solutions with coordinated and personalized care that integrates traditional treatment with out-of-hospital care and lifestyle interventions. For the “CausaHealth Diabetes Program”, we established

and verified the quantitative models of reducing glycosylated hemoglobin (HbA1c, the gold diagnosis standard for diabetes treatment) through AI-driven automated patient management, and achieved an average reduction of HbA1c by approximately 1% under a twelve-week intervention. With the maturity of the solution, we plan to expand coverage regionally to benefit more people.

As of 31 March 2022, the number of active users who completed at least one transaction during the Reporting Period on our health management platform reached 12 million.

## **Business outlook**

To achieve our mission to make value-based precision healthcare accessible to everyone and further solidify our leadership in the healthcare intelligence industry, we will continue to (i) deepen and broaden our knowledge and use-cases by disease areas, (ii) strengthen our data processing and AI capabilities to further increase our productivity, (iii) improve customer penetration and synergy among the business sectors by leveraging YiduCore's knowledge, (iv) explore opportunities in international markets, and (v) further enrich our ecosystem through strategic partnerships, investments and acquisitions.

In respect of Big Data Platform and Solutions, we will continue to strengthen our two-pronged strategy. Horizontally, we will strengthen YiduCore by (i) expanding our network of hospitals and regions, (ii) enriching the use-case scenarios of existing customers, and (iii) investing in core technology capabilities such as secure computation and explainable, computable modeled knowledge graphs to enhance the functionality, reliability and usability of our products. Vertically, we will continue to deepen and optimize our insights and knowledge within each disease area by enabling multi-site research to be carried out in our network.

In respect of Life Sciences Solutions, we will continue to accelerate the generation of research-grade evidence and drive the development of our one-stop solutions from analytics-driven clinical development to post-market commercialization in line with evolving regulations and policies. We will continue to focus on (i) generation and application of real-world evidence in various scenarios, (ii) diseases we excelled at in clinical development, (iii) enlargement and preservation of our customer base with high quality, and (iv) improvement in our operational efficiency.

In respect of Health Management Platform and Solutions, we will continue to leverage our disease insights, knowledge and expert network to provide effective health management solutions to benefit more people with “patient-centered, outcome-oriented” care. We will continue to (i) increase the number of active users on our platform from diversified channels, (ii) expand our health management product offerings to meet the multi-level mass medical needs, and (iii) enrich user experience to solidify brand loyalty.

We are well positioned to serve as a leading player in the rapidly evolving healthcare intelligence industry. In the future, we will continue to introduce innovative AI-driven applications and solutions to capture the massive market opportunities in China and beyond, to enable stakeholders in the ecosystem to derive more value from our healthcare intelligence infrastructure.

# MANAGEMENT DISCUSSION AND ANALYSIS

## Revenues

Our revenues increased by 42.7% from RMB867.0 million in the fiscal year ended 31 March 2021 to RMB1,237.2 million in the fiscal year ended 31 March 2022. The increase was primarily attributable to the increase in revenue realized from Life Science Solutions and Health Management Platform and Solutions segments.

*Big Data Platform and Solutions.* Revenue from Big Data Platform and Solutions increased by 10.7% from RMB401.9 million in the fiscal year ended 31 March 2021 to RMB444.9 million in the fiscal year ended 31 March 2022, primarily due to the increased number of active customers.

*Life Sciences Solutions.* Revenue from Life Sciences Solutions increased by 95.0% from RMB184.3 million in the fiscal year ended 31 March 2021 to RMB359.4 million in the fiscal year ended 31 March 2022, primarily due to the increased number of active customers and improved average revenue per active customer during the same periods.

*Health Management Platform and Solutions.* Revenue from Health Management Platform and Solutions increased by 68.5% from RMB252.1 million in the fiscal year ended 31 March 2021 to RMB424.9 million in the fiscal year ended 31 March 2022, primarily due to the growth of insurance services and platform solutions of CausaHealth.

*Others.* Other revenue decreased by 72.2% from RMB28.7 million in the fiscal year ended 31 March 2021 to RMB8.0 million in the fiscal year ended 31 March 2022.

## Cost of Sales and Services

Our cost of sales and services increased by 55.2% from RMB539.7 million in the fiscal year ended 31 March 2021 to RMB837.8 million in the fiscal year ended 31 March 2022. Share-based compensation expenses included in cost of sales and services were RMB7.3 million and RMB13.2 million in the fiscal years ended 31 March 2021 and 2022 respectively. The increase was caused by business expansion in Life Sciences Solutions and Health Management Platform and Solutions in the fiscal year ended 31 March 2022.

*Big Data Platform and Solutions.* Cost of sales and services from Big Data Platform and Solutions segment increased by 14.4% from RMB220.6 million in the fiscal year ended 31 March 2021 to RMB252.3 million in the fiscal year ended 31 March 2022, primarily due to (i) the increased cost of software and hardware as well as outsourcing service fee from RMB140.2 million to RMB169.5 million; (ii) increase in employee benefits and expenses of employees engaging in the Big Data Platform and Solutions business from RMB74.5 million to RMB77.4 million, which included share-based compensation expenses of RMB2.7 million and RMB7.0 million in the respective years.

*Life Sciences Solutions.* Cost of sales and services from Life Sciences Solutions increased by 87.7% from RMB144.3 million in the fiscal year ended 31 March 2021 to RMB270.8 million in the fiscal year ended 31 March 2022, primarily due to the increase in (i) employee benefits and expenses of employees engaging in the Life Science Solutions business from RMB65.9 million to RMB100.4 million, which included share-based compensation expenses of RMB3.1 million and RMB2.7 million in the respective years, and (ii) outsourcing service fee from RMB71.6 million to RMB160.7 million.

*Health Management Platform and Solutions.* Cost of sales and services from the Health Management Platform and Solutions segment increased by 105.6% from RMB149.5 million in the fiscal year ended 31 March 2021 to RMB307.3 million for the fiscal year ended 31 March 2022, primarily due to increase in cost of pharmaceutical products and services from RMB114.7 million to RMB275.4 million.

*Others.* Other cost of sales and services decreased by 70.5% from RMB25.4 million in the fiscal year ended 31 March 2021 to RMB7.5 million in the fiscal year ended 31 March 2022.

### **Gross profit and gross margin**

As a result of the foregoing, our overall gross profit in the fiscal years ended 31 March 2021 and 31 March 2022 were RMB327.3 million and RMB399.4 million, and our overall gross margin was 37.8% and 32.3% respectively.

*Big Data Platform and Solutions.* Our gross margin in Big Data Platform and Solutions decreased from 45.1% in the fiscal year ended 31 March 2021 to 43.3% in the fiscal year ended 31 March 2022, primarily attributable to revenue mix shift.

*Life Sciences Solutions.* Our gross margin in Life Sciences Solutions increased from 21.7% in the fiscal year ended 31 March 2021 to 24.7% in the fiscal year ended 31 March 2022, primarily due to increased pricing power and higher utilization.

*Health Management Platform and Solutions.* Our gross margin in Health Management Platform and Solutions decreased from 40.7% in the fiscal year ended 31 March 2021 to 27.7% in the fiscal year ended 31 March 2022, primarily driven by product mix shift.

### **Selling and marketing expenses**

Our selling and marketing expenses increased by 73.2% from RMB239.0 million in the fiscal year ended 31 March 2021 to RMB413.9 million in the fiscal year ended 31 March 2022, primarily attributable to increase in (i) employee benefits and expenses of employees engaging in selling and marketing function from RMB159.9 million to RMB234.7 million, which included share-based compensation of RMB14.6 million and RMB27.9 million in respective years; (ii) consulting and other professional fee from RMB14.1 million to RMB16.8 million; and (iii) business development, promotion and advertising expenses targeting to promote the Group's brand awareness and insurance services from RMB39.7 million to RMB105.9 million.

Selling and marketing expenses as a percentage of revenue increased from 27.6% in the fiscal year ended 31 March 2021 to 33.5% in the fiscal year ended 31 March 2022 as a result of the foregoing reasons.

### **Administrative expenses**

Our administrative expenses increased by 8.7% from RMB309.9 million in the fiscal year ended 31 March 2021 to RMB337.0 million in the fiscal year ended 31 March 2022, primarily attributable to increase in employee benefits and expenses of employees engaging in administrative function from RMB188.8 million to RMB249.3 million, which included share-based compensation of RMB94.4 million and RMB99.5 million in the respective years. This increase was partially offset by the saving of one-off listing expenses.

As a percentage of revenue, administrative expenses declined from 35.7% in the fiscal year ended 31 March 2021 to 27.2% in the fiscal year ended 31 March 2022 as our revenue grew at a faster rate.

### **Research and development expenses**

Our research and development expenses increased by 66.2% from RMB221.9 million in the fiscal year ended 31 March 2021 to RMB368.7 million in the fiscal year ended 31 March 2022. The increase in research and development expenses was primarily due to the increase in (i) employee benefit and expenses for employees engaging in research and development function from RMB183.9 million to RMB292.4 million, including share-based compensation of RMB18.3 million to RMB42.2 million in the respective years, and (ii) consulting and other professional fee from RMB17.9 million to RMB32.9 million.

Research and development expenses as a percentage of revenue increased from 25.6% in the fiscal year ended 31 March 2021 to 29.8% in the fiscal year ended 31 March 2022 as a result of the foregoing reasons.

### **Operating loss**

As a result of the foregoing, operating loss of the Group increased from RMB453.3 million in the fiscal year ended 31 March 2021 to RMB767.4 million in the fiscal year ended 31 March 2022.

### **Fair value change of convertible redeemable preferred shares**

Our fair value change of convertible redeemable preferred shares was a loss of RMB3,245.8 million and nil in the fiscal year ended 31 March 2021 and 2022 respectively.

### **Fair value change of convertible notes**

Our fair value change of convertible notes was a loss of RMB24.2 million and nil in the fiscal year ended 31 March 2021 and 2022 respectively.

## **Fair value changes of warrants**

Our fair value change of warrants was a gain of RMB34.4 million and nil in the fiscal year ended 31 March 2021 and 2022 respectively.

## **Taxation**

Income tax expenses of the Group decreased from RMB1,417 thousand in the fiscal year ended 31 March 2021 to RMB(486) thousand in fiscal year ended 31 March 2022.

## **Loss for the year**

As a result of the foregoing, our loss for the year decreased by 79.3% from RMB3,694.8 million in the fiscal year ended 31 March 2021 to RMB766.4 million in the fiscal year ended 31 March 2022, primarily due to the conversion of convertible redeemable preferred shares and convertible notes upon successful initial public offering.

## **Non-IFRS Measure — Adjusted Net Loss**

To supplement our consolidated financial statements which are presented in accordance with International Financial Reporting Standards (“**IFRS**”), we also use adjusted net loss (defined below) as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe that the presentation of this non-IFRS measure facilitates comparisons of operating performance from period to period and company to company by eliminating potential impact of items that our management does not consider to be indicative of our operating performance such as certain non-cash items and certain impact of investment transactions. We believe that this measure provides useful information to investors in understanding and evaluating the Group’s consolidated results of operations in the same manner as they help our management. However, the use of non-IFRS measure has limitations as an analytical tool, and you should not consider them in isolation from, or as a substitute for analysis of, our results of operations or financial conditions as reported under IFRS. In addition, the non-IFRS financial measure may be defined differently from similar terms used by other companies.

We define “adjusted net loss” as loss for the year and adding back (i) fair value changes of convertible redeemable preferred shares, (ii) fair value changes of convertible notes, (iii) fair value changes of warrants, (iv) share-based compensation expenses, and (v) listing expenses.

For the fiscal years ended 31 March 2021 and 2022, our adjusted net loss was RMB275.1 million and RMB583.5 million, respectively.

The following table set forth the reconciliations of our non-IFRS financial measure for the fiscal years ended 31 March 2021 and 2022 to the nearest measure prepared in accordance with IFRS.

	<b>Year ended 31 March</b>	
	<b>2022</b>	2021
	<i>(RMB'000)</i>	
Loss for the year	<b>(766,360)</b>	(3,694,817)
Add:		
Fair value changes of convertible redeemable preferred shares <sup>(1)</sup>	—	3,245,785
Fair value changes of convertible notes <sup>(2)</sup>	—	24,192
Fair value changes of warrants <sup>(3)</sup>	—	(34,398)
Share-based compensation expenses <sup>(4)</sup>	<b>182,839</b>	134,655
Listing expenses <sup>(5)</sup>	—	49,504
<b>Non-IFRS adjusted net loss</b>	<b>(583,521)</b>	(275,079)
<b>Non-IFRS adjusted net loss margin (%)<sup>(6)</sup></b>	<b>(47.2)</b>	(31.7)

(1) The non-IFRS adjustments are non-recurring in nature. Fair value changes of convertible redeemable preferred shares represent the gains or losses arising from change in fair value of our issued Series A, A-1, A-2, B and C convertible redeemable preferred shares, which was recognized as a financial liability at fair value change through profit or loss. Such changes are non-cash in nature and are not directly related to our operating activities.

(2) Fair value changes of convertible notes represent the gains or losses arising from change in fair value of our issued convertible notes, which was recognized as a financial liability at fair value change through profit or loss. Such changes are non-cash in nature and are not directly related to our operating activities.

(3) Fair value changes of warrants represent the gains or losses arising from change in fair value of the warrants we issued to our investors, which was recognized at fair value change through profit or loss. Such changes are non-cash in nature and are not directly related to our operating activities.

(4) Share-based compensation expenses relate to the share awards we offered to our employees, directors and consultants under the Share Incentive Plans, which are primarily non-cash in nature and commonly not included in similar non-IFRS measures adopted by other companies in our industry.

(5) Listing expenses are non-recurring items in nature and commonly not included in similar non-IFRS financial measures.

(6) Represents non-IFRS adjusted net loss divided by the total revenue for the period indicated.

## **Liquidity and capital resource**

During the fiscal year ended 31 March 2022, we had funded our cash requirements principally from capital contribution from shareholders and financing through issuance and sales of convertible redeemable preferred shares and convertible notes in private placement transactions. We had cash and cash equivalents, term deposits, restricted bank balance and deposits of RMB4,605.6 million and RMB3,732.1 million as of 31 March 2021 and 2022 respectively.

## **Significant investments**

The Group did not make or hold any significant investments (including any investment in an investee company with a value of 5% or more of the Company's total assets as at 31 March 2022) during the fiscal year ended 31 March 2022.

## **Material acquisitions and disposals**

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies for the fiscal year ended 31 March 2022.

## **Pledge of assets**

As at 31 March 2022, the Group had no material pledge of assets.

## **Future plans for material investments or capital asset**

As at 31 March 2022, the Group did not have detailed future plans for material investments or capital assets.

## **Foreign exchange exposure**

During the year ended 31 March 2022, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of our Company, the subsidiaries and the consolidated affiliated entities that operate in the PRC, and the subsidiary operate in the Brunei are U.S. dollar, Renminbi and Brunei dollar, respectively. Our management considers that the business is not exposed to any significant foreign exchange risk as there are no significant financial assets or liabilities denominated in the currencies other than the respective functional currencies of our group entities. For the year ended 31 March 2021 and 2022, we had net foreign exchange losses of RMB16.6 million and RMB6.6 million respectively. We did not hedge against any fluctuation in foreign currency during the fiscal years ended 31 March 2021 and 2022.

## **Contingent liabilities**

As at 31 March 2022, we did not have any material contingent liabilities (as at 31 March 2021: nil).

## **Capital commitment**

As at 31 March 2022, capital commitment of the Group was RMB2,267 thousand (as at 31 March 2021: RMB3,183 thousand), mainly for the purchase of equipment.

## Employees and remuneration

As at 31 March 2022, the Group had a total of 1,405 employees, with 820 employees based in Beijing, 217 employees in Shanghai and 368 employees in other offices in China and overseas. The following table sets forth the total number of employees by function as at 31 March 2022:

Function	Number of employees
Product Development and Technology	708
Medical Function	355
Sales and Marketing	143
General and Administrative	199
<b>Total</b>	<b>1,405</b>

Our people are our most valued assets. We are able to continue to attract the best talents across multiple domains due to their faith in the potential of YiduCore to transform healthcare. As at 31 March 2022, about 46.5% of our employees have clinical research experiences and medical background, and about 37.9% have AI and technology experiences and background. The total remuneration cost incurred by the Group for the fiscal year ended 31 March 2022 was RMB982.5 million, as compared to RMB694.5 million for the fiscal year ended 31 March 2021. The Company has also adopted a post-IPO share award scheme and a post-IPO share option scheme.

## Subsequent Event

As at the date of this announcement, the Group has no significant events occurred after the Reporting Period which require additional disclosures or adjustments.

## CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability, and the shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 15 January 2021 (the “**Listing Date**”).

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders and to enhance corporate value and accountability.

### **Compliance with the Code on Corporate Governance Practices**

For the fiscal year ended 31 March 2022, the Company has complied with the Corporate Governance Code (the “**Corporate Governance Code**”) set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), save for the following deviations.

Code provision C.2.1 of the Corporate Governance Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Ms. Gong Yingying (“**Ms. Gong**”) performs both the roles of the Chairlady of the Board and the chief executive officer of the Company. Ms. Gong is the founder of the Group and has extensive experience in the business operations and management of the Group. The Board believes that vesting the roles of both Chairlady and chief executive officer in Ms. Gong has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairperson of the Board and the chief executive officer of the Company if and when it is appropriate taking into account the circumstances of the Group as a whole.

Code provision F.1.1 of the Corporate Governance Code provides that the issuer should have a policy on payment of dividends and should disclose it in the annual report. As the Company intends to retain its available funds and earnings to fund the development and growth of our business, the performance of which will continue to be impacted by the relevant industry’s and economic outlook in the foreseeable future, the Board is of the opinion that it is not appropriate to adopt a dividend policy at this stage. The Board will review the Company’s status periodically and consider to adopt a dividend policy if and when appropriate.

## **Compliance with the Model Code for Securities Transactions by Directors**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix 10 of the Listing Rules as its own code of conduct regarding directors’ securities transactions.

Specific enquiry has been made of all the Directors and the relevant employees and they have confirmed that they have complied with the Model Code during the Reporting Period.

### **Audit committee**

The Group has established an audit committee comprising three members, being Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi, with Ms. Pan Rongrong (being the Company’s independent non-executive Director with the appropriate professional qualifications) as chair of the audit committee.

The audit committee has reviewed the audited consolidated financial statements of the Group for the fiscal year ended 31 March 2022 and has met with the independent auditor, PricewaterhouseCoopers (the “**Auditor**”). The audit committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control and financial reporting matters with senior management members of the Company.

### **Auditor’s scope of work**

The figures in respect of the Group’s consolidated statement of comprehensive income, consolidated balance sheet and the related notes thereto for the fiscal year ended 31 March 2022 contained in this announcement have been agreed by the Auditor, to the amounts set out in the audited consolidated financial statements of the Group for the fiscal year ended 31 March 2022. The work performed by the Auditor in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the Auditor on this announcement.

## OTHER INFORMATION

### Purchase, sale or redemption of the Company's listed securities

During the Reporting Period, neither the Company nor any of its subsidiaries or consolidated affiliated entities purchased, sold or redeemed any of the Company's listed securities.

### Material litigation

The Company was not involved in any material litigation or arbitration during the fiscal year ended 31 March 2022. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the Reporting Period and up to the date of this announcement.

### Use of proceeds from global offering

On 15 January 2021, the shares of the Company were listed on the Main Board of the Stock Exchange. The net proceeds from the global offering (following full exercise of the Over-allotment Option, as defined in the prospectus of the Company dated 31 December 2020 (the "Prospectus")) were approximately RMB3,825 million (the "Net Proceeds"), which are intended to be applied in the manner set out in the Prospectus. There was no change in the intended use of proceeds as previously disclosed.

Set out below is the status of use of proceeds from the global offering as at 31 March 2022 and 2021.

Purpose	% of use of proceeds	Net proceeds (RMB million)	Amount used			Expected time of full utilisation
			Unutilised amount as at 31 March 2021 (RMB million)	in the fiscal year ended 31 March 2022 (RMB million)	Unutilised amount as at 31 March 2022 (RMB million)	
Strengthen our core capabilities	35%	1,339	1,339	—	1,339	31 March 2025
Further our business expansion	35%	1,339	1,339	—	1,339	31 March 2025
Further enrich our ecosystem through strategic partnerships, investments and acquisitions	20%	765	765	—	765	31 March 2024
Working capital and general corporate purposes	10%	382	382	—	382	31 March 2025

The above Net Proceeds were translated with spot rates on the Listing Date, while the cash and cash equivalents, term deposits, restricted bank balance and deposits as of 31 March 2022 were translated with spot rates on its balance sheet date.

As disclosed on page 383 of the Prospectus, based on the current business plan, the Company intended to implement the use of proceeds from the global offering in the next three fiscal years. In light of the change of the dynamic macro-economic environment in recent years and the impact of COVID-19 which started in 2020 and re-emerged on a large scale in China in 2022, the Board currently expects full utilisation of the Net Proceeds by 31 March 2025.

### **Dividend**

The Board did not recommend the distribution of a final dividend for the fiscal year ended 31 March 2022.

### **Closure of register of members**

The Company's annual general meeting (the "AGM") will be held on 26 August 2022, Friday. The register of members of the Company will be closed for the purpose of determining the identity of members who are entitled to attend the AGM from 23 August 2022, Tuesday to 26 August 2022, Friday, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend the AGM, all duly completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, for registration, no later than 4:30 p.m. on 22 August 2022, Monday.

# Consolidated Statement of Comprehensive Income

	Year ended as at 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Revenue from contracts with customers	1,237,200	867,036
Cost of sales and services	<u>(837,755)</u>	<u>(539,700)</u>
<b>Gross profit</b>	<u>399,445</u>	<u>327,336</u>
Selling and marketing expenses	(413,934)	(239,014)
Administrative expenses	(337,032)	(309,933)
Research and development expenses	(368,659)	(221,855)
Net impairment losses on financial assets and contract assets	(48,798)	(15,578)
Impairment of non-financial assets	(12,938)	—
Other income	38,659	30,134
Other losses — net	<u>(24,141)</u>	<u>(24,376)</u>
<b>Operating loss</b>	<u>(767,398)</u>	<u>(453,286)</u>
Finance income	4,972	601
Finance costs	<u>(4,213)</u>	<u>(3,293)</u>
Finance income/(costs) — net	<u>759</u>	<u>(2,692)</u>
Share of loss from investments in associates	(207)	(1,843)
Fair value changes of convertible redeemable preferred shares	—	(3,245,785)
Fair value changes of convertible notes	—	(24,192)
Fair value changes of warrants	<u>—</u>	<u>34,398</u>
<b>Loss before income tax</b>	<u>(766,846)</u>	<u>(3,693,400)</u>
Income tax credit/(expense)	<u>486</u>	<u>(1,417)</u>
<b>Loss for the year</b>	<u>(766,360)</u>	<u>(3,694,817)</u>
<b>Loss is attributable to:</b>		
<b>Owners of the Company</b>	(762,318)	(3,700,287)
<b>Non-controlling interests</b>	<u>(4,042)</u>	<u>5,470</u>
	<u>(766,360)</u>	<u>(3,694,817)</u>

	<b>Year ended as at 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB'000</b>	<b>RMB'000</b>
<b>Other comprehensive (loss)/income</b>		
<i>Item that will not be reclassified to profit or loss:</i>		
Currency translation differences	(203,439)	470,537
Fair value changes of convertible redeemable preferred shares due to own credit risk	—	(6,762)
<i>Item that will be reclassified to profit or loss:</i>		
Currency translation differences	<u>61,632</u>	<u>102,481</u>
<b>Other comprehensive (loss)/income for the year, net of tax</b>	<u>(141,807)</u>	<u>566,256</u>
<b>Total comprehensive loss for the year</b>	<u>(908,167)</u>	<u>(3,128,561)</u>
<b>Total comprehensive loss for the year is attributable to:</b>		
<b>Owners of the Company</b>	(903,215)	(3,132,948)
<b>Non-controlling interests</b>	<u>(4,952)</u>	<u>4,387</u>
	<u>(908,167)</u>	<u>(3,128,561)</u>
<b>Loss per share, basic and diluted (RMB)</b>	<u>(0.80)</u>	<u>(7.24)</u>

# Consolidated Balance Sheet

	<b>As at 31 March</b>	
	<b>2022</b>	2021
	<i>RMB'000</i>	<i>RMB'000</i>
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	59,344	28,215
Right-of-use assets	43,381	21,359
Intangible assets	35,249	39,198
Deferred income tax assets	1,238	752
Investments accounted for using the equity method	9,915	5,217
Financial assets at fair value through profit or loss	16,461	—
Restricted bank balance and deposits	5,024	5,008
	<hr/>	<hr/>
Total non-current assets	170,612	99,749
	<hr/>	<hr/>
<b>Current assets</b>		
Inventories	5,736	31,761
Contract assets	158,749	51,440
Trade receivables	513,244	365,641
Other financial assets at amortised cost	70,656	27,043
Financial assets at fair value through profit or loss	36,927	20,945
Pledged bank deposits	—	1,268
Term deposits	318,595	3,860,723
Cash and cash equivalents	3,408,505	739,846
Other current assets	39,786	51,478
	<hr/>	<hr/>
Total current assets	4,552,198	5,150,145
	<hr/>	<hr/>
<b>Total assets</b>	<b>4,722,810</b>	<b>5,249,894</b>
	<hr/> <hr/>	<hr/> <hr/>

	<b>As at 31 March</b>	
	<b>2022</b>	2021
	<i>RMB'000</i>	<i>RMB'000</i>
<b>Equity</b>		
<b>Equity attributable to owners of the Company</b>		
Share capital	124	116
Treasury shares	(1)	(1)
Other reserves	12,227,727	12,205,187
Accumulated deficits	<u>(8,238,050)</u>	<u>(7,475,732)</u>
	<b>3,989,800</b>	4,729,570
Non-controlling interests	<u>17,666</u>	<u>22,618</u>
<b>Total equity</b>	<u><b>4,007,466</b></u>	<u><b>4,752,188</b></u>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Lease liabilities	25,987	6,909
Deferred income	<u>77,774</u>	<u>76,213</u>
<b>Total non-current liabilities</b>	<u><b>103,761</b></u>	<u>83,122</u>
<b>Current liabilities</b>		
Trade and other payables	329,506	176,616
Deferred income	10,500	10,628
Salary and welfare payable	205,656	184,451
Contract liabilities	33,256	21,179
Current income tax liabilities	245	2,189
Lease liabilities	26,178	19,521
Provisions	<u>6,242</u>	<u>—</u>
<b>Total current liabilities</b>	<u><b>611,583</b></u>	<u>414,584</u>
<b>Total liabilities</b>	<u><b>715,344</b></u>	<u><b>497,706</b></u>
<b>Total equity and total liabilities</b>	<u><b>4,722,810</b></u>	<u><b>5,249,894</b></u>

# NOTES TO FINANCIAL STATEMENTS

## 1 General information

Yidu Tech Inc. (the “**Company**”) was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability under the Companies Act of the Cayman Islands (Cap. 22, Law 3 of 1961 as consolidated and revised). The address of the Company is at Suite#4-210, Governors Square, 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands.

The Company is an investment holding company and its subsidiaries (together, the “**Group**”) are primarily engaged in the provision of the following services: (i) big data platform and solutions, ii) life sciences solutions, iii) health management platform and solutions, and iv) others in the People’s Republic of China (“**PRC**”).

This financial statements are presented in Renminbi (“**RMB**”), unless otherwise stated.

On 15 January 2021, the Company’s shares were successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Company made an offering of 156,450,000 ordinary shares (excluding any ordinary shares issued pursuant to the exercise of the over-allotment option) at a price of Hong Kong Dollar (“**HK\$**”) 26.3 per share. Additionally, the Company issued and allotted 23,467,500 ordinary shares on 10 February 2021 pursuant to the full exercise of the over-allotment option as disclosed in the announcement of the Company dated 7 February 2021. The gross proceeds received by the Company was approximately HK\$4,731,830,250 (equivalent to approximately RMB3,942,750,000). All convertible redeemable preferred shares were converted into ordinary shares upon the completion of initial public offering (“**IPO**”) on 15 January 2021.

## 2 Summary of significant accounting policies

The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

### 2.1 Basis of preparation

#### (i) Compliance with IFRS

The consolidated financial statements of the Group has been prepared in accordance with International Financial Reporting Standards (“**IFRS**”) as issued by International Accounting Standards Board (“**IASB**”).

The preparation of consolidated financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in note 4 of consolidated financial statements.

*(ii) Historical cost convention*

The consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss, convertible redeemable preferred shares, convertible notes and warrants which are carried at fair value.

*(iii) New and amended standards adopted by the Group*

The Group has applied the following standards and amendments for the first time for their annual reporting period commencing 1 April 2021:

- Amendments to IAS 37 — Onerous contract — Cost of Fulfilling a Contract
- Amendments to IAS 16 — Property, plant and equipment: Proceeds before Intended Use
- Amendments to IFRS 3 — Reference to the Conceptual Framework
- Annual improvements to IFRS standards 2018–2020

The amendments listed above did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

*(iv) New standards and interpretations not yet adopted*

The Group has not early applied the following new and amendments to IFRS that have been issued but are not yet effective:

	<b>Effective for annual periods beginning on or after</b>
IFRS 17 — Insurance Contracts	1 January 2023
Amendments to IAS 1 — Classification of Liabilities as Current or Non-current	1 January 2024
Amendments to IAS 1 and IFRS Practice Statement 2 — Disclosure of Accounting Policies	1 January 2023
Amendments to IAS 8 — Definition of Accounting Estimates	1 January 2023
Amendments to IAS 12 — Deferred Tax related to Assets and Liabilities from a Single Transaction	1 January 2023

The directors of the Company anticipate that the application of the above new standard, amendments and annual improvements will have no material impact on the Group's consolidated financial statements in the foreseeable future.

### 3 Segment information

#### *Disaggregation of revenue from contracts with customers*

The Group's business activities, for which discrete financial statements are available, are regularly reviewed and evaluated by the Chief Operating Decision Maker. As a result of this evaluation, the Group determined that it has operating segments as follows:

- Big data platform and solutions
- Life sciences solutions
- Health management platform and solutions
- Others

	Year ended 31 March 2022				
	Big data platform and solutions <i>RMB'000</i>	Life sciences solutions <i>RMB'000</i>	Health management platform and solutions <i>RMB'000</i>	Others <i>RMB'000</i>	Total <i>RMB'000</i>
Revenue from contracts with customers	444,891	359,375	424,941	7,993	1,237,200
Cost of sales and services	<u>(252,284)</u>	<u>(270,757)</u>	<u>(307,257)</u>	<u>(7,457)</u>	<u>(837,755)</u>
Gross profit	<u>192,607</u>	<u>88,618</u>	<u>117,684</u>	<u>536</u>	<u>399,445</u>

	Year ended 31 March 2021				
	Big data platform and solutions <i>RMB'000</i>	Life sciences solutions <i>RMB'000</i>	Health management platform and solutions <i>RMB'000</i>	Others <i>RMB'000</i>	Total <i>RMB'000</i>
Revenue from contracts with customers	401,884	184,318	252,129	28,705	867,036
Cost of sales and services	<u>(220,581)</u>	<u>(144,267)</u>	<u>(149,461)</u>	<u>(25,391)</u>	<u>(539,700)</u>
Gross profit	<u>181,303</u>	<u>40,051</u>	<u>102,668</u>	<u>3,314</u>	<u>327,336</u>

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the PRC. For the years ended 31 March 2022 and 2021, the Group earns approximately 81% and 19%, 80% and 20% of total revenue from external customers located in the PRC and other countries, respectively. As at 31 March 2022 and 2021, majority of the non-current assets of the Group were located in the PRC.

	<b>Year ended 31 March</b>	
	<b>2022</b>	2021
	<b><i>RMB'000</i></b>	<i>RMB'000</i>
Segment revenue		
— recognised over time	<b>520,324</b>	324,342
— recognised at a point in time	<b>716,876</b>	542,694
	<b><u>1,237,200</u></b>	<u>867,036</u>
 Segment revenue		
— gross	<b>1,130,716</b>	803,891
— net	<b>106,484</b>	63,145
	<b><u>1,237,200</u></b>	<u>867,036</u>

#### 4 Expenses by nature

Expenses included in cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses are further analysed as follows:

	Year ended 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Employee benefits expenses	982,500	694,476
Cost of sales	388,668	204,139
Outsourcing services fee	225,955	147,881
Promotion and advertising expenses	105,873	39,723
Consulting and other professional fee	92,689	64,425
Travelling, entertainment and general office expenses	77,667	40,659
Labour dispatching	21,725	17,076
Depreciation of property, plant and equipment	21,529	17,055
Depreciation of right-of-use assets	20,016	15,835
Taxes and surcharges	7,423	4,699
Listing expenses	—	49,504
Amortization of intangible assets	5,393	3,530
Auditors' remuneration — Audit services	4,918	3,243
Other expenses	3,024	8,257
	<hr/>	<hr/>
Total cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses	<u>1,957,380</u>	<u>1,310,502</u>

#### 5 Income tax (credit)/expense

	Year ended 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Current tax	—	1,944
Deferred income tax credit	(486)	(527)
	<hr/>	<hr/>
Income tax (credit)/expense	<u>(486)</u>	<u>1,417</u>

## 6 Loss per share

- (a) Basic loss per share for the years ended 31 March 2022 and 2021 are calculated by dividing the loss attributable to the Company's owners by the weighted average number of ordinary shares in issue during the years.

The calculation of loss per share is based on the following:

	Year ended 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Loss attributable to owners of the Company	<b>(762,318)</b>	(3,700,287)
Weighted average number of ordinary shares in issue ('000)	<b>957,776</b>	510,770
Basic loss per share ( <i>RMB yuan</i> )	<b><u>(0.80)</u></b>	<u>(7.24)</u>

## 7 Trade receivables

	As at 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Trade receivables from contracts with customers		
— Third parties	<b>596,746</b>	402,183
— Related parties	<b>2,227</b>	7,306
Less: allowance for impairment of trade receivables	<b><u>(85,729)</u></b>	<u>(43,848)</u>
	<b><u>513,244</u></b>	<u>365,641</u>

(a) The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 180 days. The aging analysis of the trade receivables based on invoice date is as follows:

	<b>As at 31 March</b>	
	<b>2022</b>	2021
	<i>RMB'000</i>	<i>RMB'000</i>
— Up to 3 months	<b>376,413</b>	262,524
— 3 to 6 months	<b>26,118</b>	23,163
— 6 months to 1 year	<b>87,308</b>	46,712
— 1–2 years	<b>45,746</b>	60,183
— Over 2 years	<b>63,388</b>	16,907
	<b>598,973</b>	409,489
Less: allowance for impairment of trade receivables	<b>(85,729)</b>	(43,848)
Total	<b>513,244</b>	365,641

(b) *Fair values of trade receivables*

Due to the short-term nature of the current receivables, their carrying amounts are considered to be approximately the same as their fair values.

## 8 Trade and other payables

	<b>As at 31 March</b>	
	<b>2022</b>	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Trade payables	<b>210,604</b>	85,875
Tax payables	<b>12,368</b>	8,012
Other payables:		
— Payables for consulting and other service fee	<b>36,209</b>	32,000
— Insurance premium collection payables	<b>24,680</b>	—
— Payables for repurchase of options	<b>9,928</b>	35,253
— Payables for purchase of fixed assets	<b>9,015</b>	98
— Accrual for marketing and sales promotion expenses	<b>8,228</b>	1,131
— Reimbursement payable to employees	<b>7,182</b>	7,439
— Payables for investment in venture capital fund	<b>1,904</b>	—
— Payables for leasehold improvement	<b>870</b>	120
— Amounts due to related parties	<b>66</b>	66
— Others	<b>8,452</b>	6,622
	<b>329,506</b>	176,616

(i) The carrying amounts of trade and other payables are considered to be approximated to their fair values, due to their short-term nature.

(ii) Aging analysis of the trade payables based on invoice date at the end of each reporting period are as follows:

	<b>As at 31 March</b>	
	<b>2022</b>	2021
	<b><i>RMB'000</i></b>	<i>RMB'000</i>
— Up to 3 months	<b>173,919</b>	56,222
— 3 to 6 months	<b>2,449</b>	16,120
— 6 months to 1 year	<b>23,450</b>	3,395
— 1 to 2 years	<b>9,383</b>	10,138
— 2 to 3 years	<b>1,403</b>	—
	<b><u>210,604</u></b>	<u>85,875</u>

## **9 Dividend**

No dividend has been paid or declared by the Company or the companies now comprising the Group during the years ended 31 March 2022 and 2021.

# **PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT**

This annual results announcement is published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.yidutechgroup.com](http://www.yidutechgroup.com)). The annual report of the Group for the fiscal year ended 31 March 2022 will be dispatched to the Company's shareholders and made available for review on the same websites in due course.

By order of the Board

**Yidu Tech Inc.**

**Gong Yingying**

*Chairlady, Executive Director and  
Chief Executive Officer*

Hong Kong, 24 June 2022

*As at the date of this announcement, the executive Directors are Ms. Gong Yingying, Ms. Yang Jing, Dr. Yan Jun and Ms. Zhang Shi; the non-executive Director is Mr. Zeng Ming; and the independent non-executive Directors are Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi.*